Cystic fibrosis (disorder)
Cystic Fibrosis Collection
Year Started: 2020
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 0 - 3 months |
Freezer temperature logs | 0 - 3 months |
Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | Not applicable | 100% | ||
Whole blood | -60°C to -85°C | Not applicable | 100% | ||
Sputum | -60°C to -85°C | Not applicable | 51 - 75% |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Sputum | -60°C to -85°C | Not applicable | 51 - 75% |
Acute myeloid leukemia, disease (disorder)
AML 15 Clinical Trial Collection
Year Started: 2002
Samples from the AML 15 Clinical Trial
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Treatment records | 3 - 6 months |
Female
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 75% -99% | ||
Primary cells | Liquid nitrogen vapor phase | Not applicable | 26 - 50% |
Male
Adult (> 40 years)
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 75% -99% | ||
Primary cells | Liquid nitrogen vapor phase | Not applicable | 11 - 25% |
Acute myeloid leukemia, disease (disorder)
AML 16 Clinical Trial Collection
Year Started: 2006
Samples from the AML 16 trial
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Treatment records | 3 - 6 months |
Female
Adult (> 40 years)
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Primary cells | Liquid nitrogen vapor phase | Not applicable | 11 - 25% | ||
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 75% -99% |
Male
Adult (> 40 years)
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Primary cells | Liquid nitrogen vapor phase | Not applicable | 26 - 50% | ||
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 75% -99% |
Acute myeloid leukemia, disease (disorder)
AML 17 Clinical Trial Collection
Year Started: 2007
Samples from the AML 17 trial
- Access:
- Open to applicants
- Type:
- Disease specific
- Status:
- Completed
- Consent restrictions:
- No restrictions
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Treatment records | 3 - 6 months |
Unknown
Adult (> 40 years)
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Primary cells | Liquid nitrogen vapor phase | Not applicable | 26 - 50% | ||
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen vapor phase | Not applicable | 75% -99% |